Pharmacokinetics study of mycophenolate mofetil in renal transplantation patients

OBJECTIVE To determine the steady state pharmacokinetics of mycophenolic acid (MPA), the active metabolite, after an oral administration of mycophenolate mofetil (MMF) in the kidney transplant patients. METHODS 22 Kidney transplant subjects (14 men and 8 women) were administered with a single dose of 1.0 g MMF every 12 hours and serum MPA concentrations were measured by high perfor-mance liquid chromatography (HPLC) using solid-phase extraction. The 3P87 pharmaceutical kinetics software was used for the calculation of pharmacokinetic parameters. RESULTS The means of tmax,ρmax, area under the curve (AUC0→12), mean residence time (MRT). and clearance (CL) were (1.27±1.063)h, (20.83±11.71)mg·L-1, (49.81±13.57) mg·h·L-1, (3.37±0.73)h, and (17.97±9.02) L·h-1, respectively. CONCLUSION An inter-individual variability is obtained in MPA pharmacokinetic parameters, which is consistent with the result reported previously.